查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015088

腫瘤生物相似藥市場：依產品類型、治療適應症、給藥途徑及通路分類－2026-2032年全球市場預測

Oncology Biosimilars Market by Product Type, Therapeutic Indication, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腫瘤生物相似藥市場價值將達到 77.9 億美元，到 2026 年將成長至 86.6 億美元，到 2032 年將達到 183.8 億美元，年複合成長率為 13.04%。

主要市場統計數據
基準年 2025 77.9億美元
預計年份：2026年 86.6億美元
預測年份 2032 183.8億美元
複合年成長率 (%) 13.04%

本文總結了影響治療可近性的監管、臨床引入和生產趨勢，為腫瘤生物相似藥的策略發展奠定了基礎。

腫瘤生物相似藥的發展趨勢已從小眾監管論點轉向治療可及性和商業策略的關鍵。本導言概述了重塑腫瘤藥物供應模式的許多因素，包括監管成熟度、臨床醫生接受度以及生產和製劑方面的創新。此外，本報告旨在為希望將臨床開發、商業化和供應營運與當前及短期趨勢相契合的相關人員提供策略參考。

本文探討了臨床信心、製造創新和不斷發展的商業模式如何共同重塑腫瘤生物相似藥的格局。

腫瘤生物相似藥生態系統正經歷變革性的變化，這種變化不僅體現在競爭格局上，也體現在治療方法的研發、核准以及整合到臨床診療路徑的方式。隨著核准後證據和真實世界數據的積累，臨床醫生的信心日益增強，促使指南委員會和腫瘤學會將生物相似藥納入標準治療建議。這種演變降低了處方門檻，同時也對藥物安全監測、命名規範和替代實踐提出了新的要求。

過程如何促使製造商實現生產在地化和籌資策略。

關稅和貿易措施的推出可能會對複雜的全球生技藥品供應鏈的上游環節造成巨大壓力，預計到2025年，這些措施的累積影響已促使許多相關人員重新思考籌資策略和生產基地選址。依賴進口原料藥並透過受關稅影響的路線運輸成品的製造商正在重新評估其供應商組成，導致一些公司將關鍵的上游工程本地化，或加快實施雙重採購策略，以降低貿易波動帶來的風險。

我們將分析產品、適應症、給藥途徑和分銷管道的細分，以明確腫瘤生物相似藥的不同採用趨勢。

細分市場分析揭示了產品、適應症、給藥途徑和分銷管道等方面的需求、研發重點和分銷策略的微妙模式。產品層面的趨勢受治療親和性和專利到期日的影響，其中Bevacizumab、Cetuximab昔單抗、Rituximab和曲妥珠單抗等關鍵生物類似藥候選藥物因其廣泛的腫瘤適應症和成熟的治療方案而吸引了最高的研發投入。每種分子都有其獨特的臨床、生產和商業性考量，這些因素會影響研發進度和醫療覆蓋範圍。

本研究檢視了影響全球主要地區部署和准入途徑的區域監管、採購和製造差異。

區域趨勢正在影響監管路徑、商業性准入策略和製造地，導致美洲、歐洲、中東和非洲以及亞太地區的發展各不相同。在美洲，監管政策的明確和支付方主導的成本控制正在推動許多腫瘤領域的逐步推廣，但公共和私人支付方之間的差異需要與醫療服務提供者進行細緻的合約談判和協作策略。美國複雜的報銷環境以及醫院系統作為主要購買者的角色凸顯了基於實證醫學的定位和強力的支持服務對於促進推廣的必要性。

本分析探討了成熟製造商、新興生技企業和策略夥伴關係如何透過結合生產規模、真實世界數據和服務來有效競爭。

腫瘤生物相似藥領域主要企業的舉措體現了大規模生產、策略聯盟、智慧財產權管理和差異化商業模式的整合。成熟的跨國製造商繼續利用其傳統的生物製藥專業知識和全球分銷網路，加速產品上市，並與大規模醫療系統達成有利的合約條款。這些成熟企業將其生物相似藥產品組合與完善的藥物安全監測系統和患者支持服務相結合，力求在確保醫保覆蓋和報銷條件的同時，增強臨床醫生和支付方的信心。

為高階主管提供切實可行的策略建議，透過協調證據產生、供應彈性和商業服務，推動生物相似藥的永續採用。

致力於在腫瘤生物相似藥領域實現永續成長的產業領導者應優先考慮整合臨床證據、商業性可行性和供應韌性的整合策略。首先，投資於嚴謹的真實世界證據（RWE）項目，主動監測不同適應症和給藥途徑的安全性和有效性。這些數據將加速臨床醫生對產品的接受度，支持與支付方的談判，並為上市後最佳化工作提供寶貴資訊。其次，實現製造地多元化，並對關鍵原料實施雙重供應和儲備，以維持快速回應市場需求的能力，同時降低貿易和關稅風險。

本文檔描述了一種混合方法研究途徑，該方法整合了相關人員訪談、監管審查、索賠資料分析和情境規劃，並檢驗了策略見解。

本分析的調查方法結合了定性和定量方法，以確保研究結果的穩健性和實用性。主要研究包括對各類相關人員進行結構化訪談，包括臨床腫瘤學家、醫院藥劑師、專科藥房經理、生產企業高管和支付方代表，以了解他們對推廣應用障礙、合約偏好和營運限制的最新觀點。除訪談外，還與監管和供應鏈專家舉行了有針對性的聽證會，以了解不斷變化的核准途徑和物流對相關問題的影響。

這個結論總結了證據、供應韌性和服務導向的商業化如何決定腫瘤生物相似藥的長期成功。

總之，本研究整合了其核心發現，並重申了腫瘤生物相似藥相關利害關係人相關人員的關鍵策略挑戰。臨床認可度日益依賴真實世界數據的累積和與臨床醫生的系統性互動，而生產現代化和分銷柔軟性正成為成功上市的關鍵差異化因素。關稅相關的干擾正在促使供應鏈徹底重組，凸顯了多元化採購和彈性物流規劃的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：腫瘤生物相似藥市場：依產品類型分類

  • Bevacizumab
  • Cetuximab
  • Rituximab
  • 曲妥珠單抗

第9章：依治療適應症分類的腫瘤生物相似藥市場

  • 乳癌
  • 結腸癌
  • 胃癌
  • 肺癌
  • 非何傑金氏淋巴瘤

第10章：腫瘤生物相似藥市場：依給藥途徑分類

  • 靜脈注射
  • 皮下注射

第11章：腫瘤生物相似藥市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第12章 腫瘤生物相似藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：腫瘤生物相似藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 腫瘤生物相似藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國腫瘤生物相似藥市場

第16章：中國腫瘤生物相似藥市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-036C5CF3A8CC

The Oncology Biosimilars Market was valued at USD 7.79 billion in 2025 and is projected to grow to USD 8.66 billion in 2026, with a CAGR of 13.04%, reaching USD 18.38 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.79 billion
Estimated Year [2026] USD 8.66 billion
Forecast Year [2032] USD 18.38 billion
CAGR (%) 13.04%

Establishing the strategic context for oncology biosimilars by summarizing regulatory, clinical adoption, and manufacturing trends shaping therapeutic access

The oncology biosimilars landscape has transitioned from niche regulatory debates into a pivotal axis of therapeutic access and commercial strategy. This introduction summarizes the converging forces reshaping oncology care delivery, including regulatory maturation, clinician adoption, and innovations in manufacturing and formulation. It establishes the report's purpose as a strategic reference for stakeholders seeking to align clinical development, commercialization, and supply operations with current and near-term dynamics.

The rise of biosimilars in oncology reflects a broader shift toward sustainable biologic utilization. Over recent years regulatory bodies have clarified pathways for approval and interchangeability, while payers and providers have increasingly factored biosimilars into formulary design, contracting, and treatment algorithms. At the same time, manufacturers have pursued diverse strategies, from demonstrating clinical equivalence to optimizing cost-to-serve through manufacturing modernization and alternative routes of administration. This introduction frames those developments and articulates how they collectively influence prescribing behavior, patient access, and competitive positioning.

By setting out these foundational themes, the introduction prepares stakeholders to engage with detailed analyses across regulatory, clinical, commercial, and operational dimensions. It emphasizes practical implications for clinicians, hospital systems, specialty pharmacies, and manufacturers, and highlights where targeted interventions can accelerate uptake, ensure supply resilience, and improve the overall value proposition of oncology biosimilars.

Exploring how clinical trust, manufacturing innovation, and commercial model evolution are collectively reshaping the oncology biosimilars landscape

The oncology biosimilars ecosystem is experiencing transformative shifts that extend beyond price competition to alter how therapies are developed, approved, and integrated into care pathways. Clinician confidence has grown as post-approval evidence and real-world data accumulate, prompting guideline committees and oncology societies to incorporate biosimilars into standard treatment recommendations. This evolution reduces barriers to prescribing while creating new expectations around pharmacovigilance, naming conventions, and substitution practices.

Simultaneously, manufacturing innovation is redefining competitive advantage. Advances such as single-use technologies, intensified upstream processes, and decentralized fill-finish options enable more flexible capacity deployment and lower capital intensity. These capabilities support faster scale-up for biosimilar launches and improve supply resilience, which in turn informs contracting strategies with health systems and payers. In parallel, formulation innovation, particularly the emergence of subcutaneous delivery for agents historically administered intravenously, reshapes care settings and patient experience, enabling faster infusion times, reduced clinic burden, and potential shifts in reimbursement models.

Commercial models are also morphing: value-based arrangements, outcomes-linked contracts, and distribution partnerships are being piloted to align incentives across manufacturers, payers, and providers. Digital platforms and patient support solutions are increasingly leveraged to enhance adherence and manage safety reporting. Collectively, these trends signal a market moving toward integrated, evidence-driven adoption where clinical trust, supply chain agility, and commercial creativity determine long-term leadership.

Assessing how tariffs, trade measures, and supply chain realignment through 2025 have prompted manufacturers to localize production and diversify sourcing strategies

The imposition of tariffs and trade measures can exert significant upstream pressure across complex global biologics supply chains, and the cumulative impact projected through 2025 has reshaped procurement calculus and production footprints for many stakeholders. Manufacturers dependent on active pharmaceutical ingredient imports or on finished-dose transit across tariff-affected routes have re-evaluated supplier segmentation, leading some to localize critical upstream steps and to accelerate dual-sourcing strategies to mitigate exposure to trade volatility.

These adjustments have operational consequences: suppliers have had to reconfigure logistics networks, increase inventory buffers for critical raw materials, and re-assess cost-to-serve models when delivering to major payers and hospital systems. Procurement teams have intensified supplier qualification timelines and included tariff sensitivity analysis in contracting clauses to ensure continuity of supply. For payers and providers, increased landed costs in some channels have prompted closer scrutiny of procurement practices and greater interest in alternative sourcing arrangements, including domestic manufacturing partnerships and contracted exclusivities that secure volume and pricing predictability.

Regulatory and commercial teams have concurrently focused on scenario planning, modeling the operational and contracting implications of persistent tariff regimes. The result is a more deliberate alignment of manufacturing site selection, supply chain design, and commercialization timing to reduce exposure to trade-related cost shocks while preserving the clinical and economic value propositions that underpin biosimilar adoption.

Unpacking product, indication, administration route, and channel segmentation to reveal differentiated adoption dynamics across oncology biosimilars

Segmentation analysis reveals nuanced patterns of demand, development focus, and distribution strategy across the product, indication, route of administration, and channel axes. Product-level dynamics are shaped by therapeutic familiarity and patent expiration timelines, with leading biosimilar candidates including bevacizumab, cetuximab, rituximab, and trastuzumab attracting the greatest development intensity due to their broad oncology indications and well-established treatment protocols. Each molecule presents unique clinical, manufacturing, and commercial considerations that influence development timelines and formulary positioning.

Therapeutic indication segmentation-spanning breast cancer, colorectal cancer, gastric cancer, lung cancer, and non-Hodgkin's lymphoma-drives heterogeneity in adoption patterns. Indications with standardized treatment pathways and high volumes tend to facilitate faster uptake, whereas rarer or more complex indications may require additional evidence generation and targeted clinician engagement. Route of administration further differentiates value propositions: intravenous infusion remains predominant for many oncology biologics, while subcutaneous injection offers opportunities to reduce infusion center burden and improve patient convenience, thereby affecting site-of-care economics and payer negotiations.

Distribution channel segmentation, which includes hospital pharmacies, online pharmacies, retail pharmacies, and specialty pharmacies, introduces additional layers of complexity. Hospital pharmacies remain central for inpatient oncology care and high-cost infusions, specialty pharmacies play a major role in managing complex biologic therapies and support services, while online and retail channels are increasingly relevant for outpatient and maintenance therapies. Understanding how these four segmentation axes intersect is essential for designing targeted commercialization, patient support, and distribution strategies that align with clinician workflows and payer incentives.

Examining regional regulatory, procurement, and manufacturing differences that shape differentiated adoption and access pathways across major global territories

Regional dynamics influence regulatory pathways, commercial access strategies, and manufacturing placement, producing divergent trajectories across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory clarity and payer-driven cost containment have facilitated progressive adoption in many oncology settings, though variability across public and private payers necessitates nuanced contracting and provider engagement strategies. The United States' complex reimbursement landscape and the role of hospital systems as major purchasers underscore the need for evidence-based positioning and robust support services to drive uptake.

Europe, Middle East & Africa display a heterogeneous regulatory and procurement environment where centralized and national-level policies interact. Several European healthcare systems have been early adopters of biosimilars, often leveraging tendering mechanisms and national procurement to accelerate adoption, while Middle East and Africa regions vary widely in regulatory maturity and access infrastructure, requiring localized regulatory strategies and commercial partnerships. In Asia-Pacific, manufacturing capacity, a growing biologics R&D base, and differing regulatory pathways are shaping both supply and demand. Several Asia-Pacific markets are characterized by strong domestic manufacturing capabilities and government initiatives that encourage biosimilar use, while others prioritize import reliance and regulatory alignment with established authorities.

These regional distinctions affect clinical evidence requirements, contracting approaches, and distribution models. Stakeholders must therefore tailor regulatory submissions, real-world evidence generation, and market entry sequencing to match region-specific payer levers, clinical practice patterns, and manufacturing-sourcing logics.

Analyzing how incumbent manufacturers, biotech entrants, and strategic partnerships are combining production scale, real-world evidence, and services to compete effectively

Key company behaviors in the oncology biosimilars arena reflect a blend of scale manufacturing, strategic partnerships, intellectual property navigation, and differentiated commercial models. Established multinational manufacturers continue to deploy legacy biologics expertise and global distribution networks to accelerate product launches and to secure favorable contracting arrangements with large health systems. These incumbents often pair biosimilar portfolios with robust pharmacovigilance and patient support services to reassure clinicians and payers while defending coverage and reimbursement positions.

Biotech-focused entrants and joint ventures are leveraging nimble development processes, localized manufacturing, and cost-efficient production techniques to compete on price and speed-to-market. Partnerships between originator companies and biosimilar developers, as well as licensing agreements, have become commonplace, creating hybrid strategies that combine regulatory know-how with manufacturing economies. Legal and patent challenges continue to shape launch timing and competitive dynamics, prompting companies to diversify pipelines and to pursue indications with clearer pathways to adoption.

Commercial differentiation increasingly centers on services as much as price. Companies that invest in remote monitoring, adherence programs, digital support tools, and streamlined specialty pharmacy integration tend to achieve deeper penetration in outpatient settings. Additionally, firms that articulate clear interchangeability or substitution strategies and that invest in real-world evidence generation strengthen their negotiating position with payers and hospital systems, reinforcing the competitive interplay between clinical credibility and operational excellence.

Actionable strategic recommendations for executives to align evidence generation, supply resilience, and commercial services to drive durable biosimilar adoption

Industry leaders seeking sustainable growth in oncology biosimilars should prioritize integrated strategies that align clinical evidence with commercial execution and supply resilience. First, invest in rigorous real-world evidence programs that actively monitor safety and effectiveness across indications and routes of administration; these data accelerate clinician acceptance, support payer negotiations, and inform post-launch optimization efforts. Second, diversify manufacturing footprints and implement dual-sourcing and buffer inventories for critical materials to mitigate trade and tariff exposures while preserving rapid launch capability.

Third, adopt differentiated patient and provider support models that address the specific needs of oncology care pathways, including streamlined prior authorization support, infusion center coordination, and adherence programs for subcutaneous administration where applicable. Fourth, engage payers proactively with value-based contracting pilots and outcomes-linked agreements that align reimbursement with demonstrated clinical performance and total cost-of-care improvements. Fifth, pursue targeted partnerships and licensing arrangements to broaden geographic reach and to share development risk, particularly in regions with distinct regulatory requirements or tender-driven procurement models.

Finally, integrate digital tools for supply chain visibility, remote patient support, and clinician education to accelerate uptake and to reduce friction in adoption. Executed together, these recommendations provide a practical roadmap for leaders to convert scientific equivalence into durable commercial value and to ensure that supply and service capabilities support long-term adoption across care settings.

Describing a mixed-methods research approach that integrates stakeholder interviews, regulatory review, claims analysis, and scenario planning to validate strategic insights

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure robustness and practical relevance. Primary research included structured interviews with a cross-section of stakeholders such as clinical oncologists, hospital pharmacists, specialty pharmacy leads, manufacturing executives, and payer representatives to capture contemporary perspectives on adoption barriers, contracting preferences, and operational constraints. These interviews were complemented by targeted outreach to regulatory experts and supply chain specialists to understand evolving approval pathways and logistics implications.

Secondary research entailed systematic review of regulatory guidance documents, clinical trial publications, real-world evidence studies, and public filings to triangulate findings and to map development and approval timelines. Commercial and procurement trends were analyzed using anonymized claims and dispensing datasets where available, together with tender notices and formulary updates, to identify shifting utilization patterns and payer levers. Analytical techniques included thematic synthesis of qualitative inputs, scenario planning for tariff and supply chain contingencies, and comparative assessment across product, indication, administration route, and distribution channel segments.

Quality assurance measures comprised cross-validation of key insights with independent experts, iterative hypothesis testing against emerging data, and transparent documentation of assumptions. This mixed-methods approach ensures the report's recommendations are grounded in practical evidence and calibrated to the operational realities confronting manufacturers, providers, and payers.

Concluding synthesis that distills how evidence, supply resilience, and service-oriented commercialization together determine long-term success for oncology biosimilars

The conclusion synthesizes the study's central insights and reiterates the strategic imperatives for stakeholders engaged in oncology biosimilars. Clinical acceptance is increasingly driven by accumulated real-world evidence and by concerted clinician outreach, while manufacturing modernization and distribution flexibility are becoming decisive differentiators in launch success. Tariff-related disruptions have prompted meaningful supply chain reengineering, underscoring the need for diversified sourcing and resilient logistics planning.

Commercial success will hinge on pairing clinical credibility with tailored service models that address the operational realities of oncology care, including site-of-care economics and patient convenience. Regional regulatory and procurement heterogeneity necessitates tailored entry sequencing and evidence-generation plans that align with local payer levers and clinical guidelines. Companies that combine robust post-approval evidence, strategic partnerships, and digital-enabled patient support will be better positioned to convert clinical equivalence into sustainable utilization.

In sum, the future of oncology biosimilars will be determined by an integrated focus on evidence, supply resilience, and service-driven commercialization. Stakeholders that act now to align these elements will maximize both clinical impact and commercial viability while supporting broader goals of access and affordability in oncology care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology Biosimilars Market, by Product Type

  • 8.1. Bevacizumab
  • 8.2. Cetuximab
  • 8.3. Rituximab
  • 8.4. Trastuzumab

9. Oncology Biosimilars Market, by Therapeutic Indication

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Gastric Cancer
  • 9.4. Lung Cancer
  • 9.5. Non-Hodgkin's Lymphoma

10. Oncology Biosimilars Market, by Route Of Administration

  • 10.1. Intravenous Infusion
  • 10.2. Subcutaneous Injection

11. Oncology Biosimilars Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies
  • 11.4. Specialty Pharmacies

12. Oncology Biosimilars Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oncology Biosimilars Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oncology Biosimilars Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Oncology Biosimilars Market

16. China Oncology Biosimilars Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Amgen Inc.
  • 17.6. Biocon Limited
  • 17.7. Celltrion, Inc.
  • 17.8. Dr. Reddy's Laboratories Limited
  • 17.9. Eli Lilly and Company
  • 17.10. Fresenius Kabi AG
  • 17.11. Pfizer Inc.
  • 17.12. Samsung Bioepis Co., Ltd.
  • 17.13. Sandoz AG
  • 17.14. Teva Pharmaceutical Industries Ltd.
  • 17.15. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY CETUXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY CETUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY CETUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY TRASTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY TRASTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GASTRIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GASTRIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)